liraglutide
释义
利拉鲁肽；
英英释义
Liraglutide
Liraglutide (NN2211), marketed under the brand name Victoza, is a long-acting glucagon-like peptide-1 agonist (GLP-1 agonist) developed by Novo Nordisk for the treatment of type 2 diabetes. The product was approved by the European Medicines Agency (EMA) on July 3, 2009, and by the U.
以上来源于:Wikipedia
权威例句
LiraglutideLiraglutide
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parall...
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-l...
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic an...
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD...
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lo...
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the ...
One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia a...
1. This is also true for the other agents like liraglutide and sitagliptin.
其他药物如利拉鲁肽和西格列汀也是如此。
youdao
2. "Humans lack the C-cell receptors that liraglutide ACTS on," he asserted.
“人类缺失依拉鲁肽作用的C细胞受体，”他断言。
youdao
3. Liraglutide is given once per day and it doesn't really matter when, which gives flexibility to patients.
利拉鲁肽每天使用一次，但患者可以灵活使用。
youdao
4. Novo has a whole three-phase program regarding obesity and liraglutide now, and we are waiting for the results we will see.
诺和诺德公司制定了一个针对肥胖人群采用利拉鲁肽进行干预的三期项目规划，期待着结果的公布。
youdao
5. Nausea was the most commonly reported adverse event with both agents, with slightly less persistent nausea in the liraglutide group than in the exenatide group.
两种药使用中报告频率最多的不良反应是呕吐，依拉鲁肽组相比依克那肽组持续呕吐的发生要稍轻些。
youdao
6. Liraglutide stimulates C-cells in rodents, causing an increase in calcitonin and there were few cases of cancer in these animals, but there were none in nonhuman primates nor in any humans.
依拉鲁肽刺激啮齿类动物的C细胞使其降钙素生成增加并有部分实验动物发生肿瘤，但未观察到有人类发生此类严重副作用。
youdao
7. With liraglutide, they have very low occurrences of hypoglycemic events and also they do not increase but data mainly shows that it decreases body weight so that is a beneficial for type 2 diabetes.
而利拉鲁肽治疗低血糖事件的发生率非常低，并且数据显示它不仅不增加反而降低体重，而这对于2型糖尿病患者是有益的。
youdao
8. With liraglutide, they have very low occurrences of hypoglycemic events and also they do not increase but data mainly shows that it decreases body weight so that is a beneficial for type 2 diabetes.
而利拉鲁肽治疗低血糖事件的发生率非常低，并且数据显示它不仅不增加反而降低体重，而这对于2型糖尿病患者是有益的。
youdao
liraglutide
